Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: A single centre experience

Archives of Gynecology and Obstetrics

Volumn 282, Issue 4, 2010, Pages 417-425

  Bilici, Ahmet ^a   Salepci, Taflan ^a   Dane, Faysal ^b   Gumus, Mahmut ^a   Ustaalioglu, Bala Basak Oven ^a   Seker, Mesut ^a   Salman, Tarik ^a   Turan, Cem ^a   Unal, Orhan ^a   Yaylaci, Mustafa ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Advanced stage; Epithelial type; Neoadjuvant chemotherapy; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; PACLITAXEL; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL TYPE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL INDICATOR; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG RESPONSE; EPITHELIUM TUMOR; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION RESPONSE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77957311254     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1330-7     Document Type: Article

References (45)

1. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66 10.3322/canjclin.57.1.43 17237035
2. SA Cannistra 2004 Cancer of the ovary N Engl J Med 351 2519 2529 1:CAS:528:DC%2BD2cXhtVGksbbM 10.1056/NEJMra041842 15590954 (Pubitemid 39603165)
3. Karlan BY, Markman MA, Eifel PJ (2005) Ovarian cancer, peritoneal carcinoma and fallopian tube carcinoma. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 7th edn edn. Williams and Wilkins, Lippincott, pp 1364-1397
4. BB Yeole AV Kumar A Kurkure L Sunny 2004 Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India Asian Pac J Cancer Prev 5 308 315 15373712
5. CH Holschneider JS Berek 2000 Ovarian cancer: epidemiology, biology, and prognostic factors Semin Surg Oncol 19 3 10 1:STN:280:DC%2BD3cvgslehsg%3D%3D 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S 10883018 (Pubitemid 30439309)
6. CM Beard LC Hartmann EJ Atkinson PC O'Brien GD Malkasian GL Keeney LJ Melton III 2000 The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991 Ann Epidemiol 10 14 23 1:STN:280: DC%2BD3c7itFOksA%3D%3D 10.1016/S1047-2797(99)00045-9 10658685 (Pubitemid 30038214)
7. WJ Hoskins WP McGuire MF Brady HD Homesley WT Creasman M Berman H Ball JS Berek 1994 The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 974 979 1:STN:280:DyaK2c3hvFGntQ%3D%3D 8166218
8. WJ Hoskins BN Bundy JT Thigpen GA Omura 1992 The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 47 159 166 1:STN:280:DyaK3s7gs1Cqsw%3D%3D 10.1016/0090-8258(92)90100-W 1468693 (Pubitemid 23001322)
9. RE Bristow RS Tomacruz DK Armstrong EL Trimble FJ Montz 2002 Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 1248 1259 10.1200/JCO.20.5. 1248 11870167 (Pubitemid 34177431)
10. S Tangjitgamol S Manusirivithaya M Laopaiboon P Lumbiganon 2009 Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review Gynecol Oncol 112 257 264 10.1016/j.ygyno.2008.09.041 19017548
11. Y Ansquer E Leblanc K Clough P Morice J Dauplat P Mathevet C Lhommé C Scherer JD Tigaud M Benchaib E Fourme D Castaigne D Querleu D Dargent 2001 Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study Cancer 91 2329 2334 1:STN:280:DC%2BD3MzkvFGrsw%3D%3D 10.1002/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.0.CO;2-U 11413522 (Pubitemid 32552819)
12. ME van der Burg 2001 Advanced ovarian cancer Curr Treat Options Oncol 2 109 118 10.1007/s11864-001-0053-1 12057129
13. P Fioretti A Gadducci B Del Bravo B Prato 1990 The potential of primary cytoreductive surgery in patients with FIGO stages III and IV ovarian carcinoma Eur J Gynaecol Oncol 11 175 179 1:STN:280:DyaK3M%2Fgs1WqtA%3D%3D 2209635
14. F Mazzeo M Berlière J Kerger J Squifflet L Duck V D'Hondt Y Humblet J Donnez JP Machiels 2003 Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer Gynecol Oncol 90 163 169 1:CAS:528: DC%2BD3sXkvVaqsLs%3D 10.1016/S0090-8258(03)00249-X 12821358 (Pubitemid 37338092)
15. YM Chan TY Ng HY Ngan LC Wong 2003 Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study Gynecol Oncol 88 9 16 1:STN:280:DC%2BD38jktFKntw%3D%3D 10.1006/gyno.2002.6849 12504620 (Pubitemid 36062659)
16. T Giannopoulos S Butler-Manuel A Taylor N Ngeh H Thomas 2006 Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma Eur J Gynaecol Oncol 27 25 28 1:STN:280:DC%2BD287mtFyitg%3D%3D 16550963
17. FG Lawton CW Redman DM Luesley KK Chan G Blackledge 1989 Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer Obstet Gynecol 73 61 65 1:STN:280:DyaL1M%2FntFWguw%3D%3D 2462202
18. JH Jacob DM Gershenson M Morris LJ Copeland TW Burke JT Wharton 1991 Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer Gynecol Oncol 42 146 150 1:STN:280:DyaK3Mznt1KntQ%3D%3D 10.1016/0090-8258(91)90335-3 1894174
19. JY Hou MG Kelly H Yu JN McAlpine M Azodi TJ Rutherford PE Schwartz 2007 Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease Gynecol Oncol 105 211 217 1:CAS:528:DC%2BD2sXjsVemsLk%3D 10.1016/j.ygyno.2006.11.025 17239941 (Pubitemid 46441463)
20. D Pectasides D Farmakis A Koumarianou 2005 The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer Oncology 68 64 70 1:CAS:528:DC%2BD2MXjslCgur8%3D 10.1159/000084822 15809522 (Pubitemid 40675011)
21. W Kuhn S Rutke K Späthe B Schmalfeldt G Florack B von Hundelshausen D Pachyn K Ulm H Graeff 2001 Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma Cancer 92 2585 2591 1:CAS:528:DC%2BD3MXovVWnurY%3D 10.1002/1097-0142(20011115)92: 10<2585::AID-CNCR1611>3.0.CO;2-# 11745193 (Pubitemid 33049442)
22. E Surwit J Childers I Atlas M Nour K Hatch A Hallum D Alberts 1996 Neoadjuvant chemotherapy for advanced ovarian cancer Int J Gynecol Cancer 6 356 366 10.1046/j.1525-1438.1996.06050356.x (Pubitemid 26268895)
23. V Loizzi G Cormio L Resta CA Rossi AR Di Gilio A Cuccovillo L Selvaggi 2005 Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study Int J Gynecol Cancer 15 217 223 1:STN:280:DC%2BD2M7ptVyisw%3D%3D 10.1111/j.1525-1438.2005.15206.x 15823102 (Pubitemid 40396955)
24. P Morice G Dubernard A Rey D Atallah P Pautier C Pomel C Lhommé P Duvillard D Castaigne 2003 Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer J Am Coll Surg. 197 955 963 10.1016/j.jamcollsurg.2003.06.004 14644284 (Pubitemid 38199555)
25. SJ Lee BG Kim JW Lee CS Park JH Lee DS Bae 2006 Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery J Obstet Gynaecol Res 32 99 106 1:CAS:528:DC%2BD28XjtlWrtr8%3D 10.1111/j.1447-0756.2006.00359.x 16445534
26. F Kayikçioglu MF Köse N Boran E Calişkan G Tulunay 2001 Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma Int J Gynecol Cancer 11 466 470 10.1046/j.1525-1438.2001.01064.x 11906550 (Pubitemid 34024805)
27. I Vergote I De Wever W Tjalma M Van Gramberen J Decloedt P van Dam 1998 Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol Oncol 71 431 436 1:STN:280:DyaK1M7gs1SqtQ%3D%3D 10.1006/gyno.1998.5213 9887245 (Pubitemid 29022333)
28. ME van der Burg M van Lent M Buyse A Kobierska N Colombo G Favalli AJ Lacave M Nardi J Renard S Pecorelli 1995 The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer N Engl J Med. 332 629 634 10.1056/NEJM199503093321002 7845426
29. GD Aletti SC Dowdy KC Podratz WA Cliby 2007 Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system Gynecol Oncol 105 84 89 10.1016/j.ygyno.2006.10.055 17157903 (Pubitemid 46441445)
30. A Fagotti G Ferrandina F Fanfani G Garganese G Vizzielli V Carone MG Salerno G Scambia 2008 Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma Am J Obstet Gynecol. 199 642.e1 646.e1 10.1016/j.ajog.2008.06.052
31. SS Chen R Bochner 1985 Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma Gynecol Oncol 20 190 195 1:STN:280:DyaL2M7ivVKitA%3D%3D 10.1016/0090-8258(85)90141-6 3972286 (Pubitemid 15133014)
32. S Sharma D Driscoll K Odunsi A Venkatadri S Lele 2005 Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients Am J Obstet Gynecol 193 2077 2082 10.1016/j.ajog.2005.06.074 16325619 (Pubitemid 41737638)
33. DS Chi CC Franklin DA Levine F Akselrod P Sabbatini WR Jarnagin R DeMatteo EA Poynor NR Abu-Rustum RR Barakat 2004 Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach Gynecol Oncol 94 650 654 10.1016/j.ygyno.2004.01.029 15350354 (Pubitemid 39194456)
34. ME van der Burg C Coens M van Lent A Kobierska N Colombo G Favalli 2005 The survival benefit of interval debulking surgery (IDS) in advanced ovarian cancer maintained during ten years; the EORTC GCG 55865 study Int J Gynecol Cancer 15 Suppl 2 79
35. CW Redman J Warwick DM Luesley R Varma FG Lawton GR Blackledge 1994 Intervention debulking surgery in advanced epithelial ovarian cancer Br J Obstet Gynaecol 101 142 146 1:STN:280:DyaK2c7jslKltQ%3D%3D 8305389
36. PG Rose S Nerenstone MF Brady D Clarke-Pearson G Olt SC Rubin DH Moore JM Small 2004 Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 351 2489 2497 1:CAS:528: DC%2BD2cXhtVGksbnO 10.1056/NEJMoa041125 15590951 (Pubitemid 39603156)
37. F Fanfani G Ferrandina G Corrado A Fagotti HV Zakut S Mancuso G Scambia 2003 Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients Oncology 65 316 322 10.1159/000074644 14707451 (Pubitemid 38064943)
38. A Onnis M Marchetti P Padovan L Castellan 1996 Neoadjuvant chemotherapy in advanced ovarian cancer Eur J Gynaecol Oncol 17 393 396 1:STN:280: DyaK2s%2Fosl2jsg%3D%3D 8933839
39. Vergote CG, Tropé F, Amant GB, Kristensen JE, Sardi T, Ehlen N, Johnson RHM, Verheijen MEL, van der Burg AJ, Lacave P, Benedetti Panici GG, Kenter A, Casado C, Mendiola C, Coens G, Stuart S, Pecorelli NS (2008) EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer. Plenary presentation at the 12th Biennial meeting International Gynecologic Cancer Society IGCS, Bangkok, Thailand October 25-28, 2008 (abs.)
40. ME van der Burg I Vergote 2003 Gynecological Cancer Group of the EORTC. The role of interval debulking surgery in ovarian cancer Curr Oncol Rep 5 473 481 10.1007/s11912-003-0008-8 14521806
41. EE Voest JC van Houwelingen JP Neijt 1989 A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log relative risk) as main objectives Eur J Cancer Clin Oncol 25 711 720 1:STN:280:DyaL1M3jtF2jug%3D%3D 10.1016/0277-5379(89)90208-3 2714347 (Pubitemid 19096441)
42. A Rafii B Deval JF Geay N Chopin X Paoletti D Paraiso E Pujade-Lauraine 2007 Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study Int J Gynecol Cancer. 17 777 783 1:STN:280:DC%2BD2svhsFKitA%3D%3D 10.1111/j.1525-1438. 2007.00905.x 17367318 (Pubitemid 47063342)
43. RE Bristow FJ Montz LD Lagasse RS Leuchter BY Karlan 1999 Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer Gynecol Oncol 72 278 287 1:STN:280:DyaK1M7msVWhuw%3D%3D 10.1006/gyno.1998.5145 10053096 (Pubitemid 29118182)
44. PC Liu I Benjamin MA Morgan SA King JJ Mikuta SC Rubin 1997 Effect of surgical debulking on survival in stage IV ovarian cancer Gynecol Oncol 64 4 8 1:STN:280:DyaK2s7ltFSjsQ%3D%3D 10.1006/gyno.1996.4396 8995539 (Pubitemid 27026948)
45. S Pignata G Scambia A Savarese E Breda R Sorio C Pisano D Lorusso F Cognetti A Vernaglia Lombardi V Gebbia P Scollo A Morabito G Signoriello F Perrone 2009 Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial Oncology 76 49 54 1:CAS:528:DC%2BD1cXhsFarsbbP 10.1159/000178760 19039248